Core Insights - Jazz Pharmaceuticals reported revenue of $1.09 billion for the quarter ended December 2024, reflecting a year-over-year increase of 7.5% and an EPS of $6.60, up from $5.02 in the same quarter last year, surpassing both revenue and EPS consensus estimates [1] Revenue Performance - Product sales netted $1.03 billion, exceeding the average analyst estimate of $995.17 million, with a year-over-year change of +6% [4] - Oncology product Defitelio/defibrotide generated $57.65 million, surpassing the nine-analyst average estimate of $46.52 million, marking a +12.9% year-over-year change [4] - Neuroscience product Oxybate (Xywav) achieved $400.96 million, exceeding the average estimate of $393.28 million, with a +19% year-over-year change [4] - Neuroscience product Epidiolex/Epidyolex reported $275.05 million, compared to the average estimate of $264.59 million, reflecting a +14.3% year-over-year change [4] - Neuroscience product Sativex generated $5.17 million, slightly below the average estimate of $6.58 million, with a +0.7% year-over-year change [4] - Total revenues from Neuroscience reached $730.47 million, exceeding the average estimate of $714.23 million, with a +5.9% year-over-year change [4] - Total revenues from Oncology amounted to $291.76 million, surpassing the average estimate of $276.22 million, with a +6.6% year-over-year change [4] - Rylaze generated $101.49 million, slightly below the average estimate of $99.81 million, with a -0.3% year-over-year change [4] - Vyxeos achieved $53.25 million, exceeding the average estimate of $42.05 million, with a +13.5% year-over-year change [4] - Zepzelca reported $78.33 million, below the average estimate of $91.31 million, with a +5.8% year-over-year change [4] - Other revenues totaled $2.97 million, below the average estimate of $3.84 million, reflecting a -27.3% year-over-year change [4] Stock Performance - Jazz Pharmaceuticals' shares returned +9.9% over the past month, contrasting with the Zacks S&P 500 composite's -1.8% change, indicating strong relative performance [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

February 25, 2025 2024 Fourth Quarter and Full Year Financial Results Innovating to Transform the Lives of Patients and Their Families EPIDIOLEX® patient diagnosed with Dravet syndrome February 25, 2025 Markella Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, in ...

Group 1 - Jazz Pharmaceuticals reported quarterly earnings of $6.60 per share, exceeding the Zacks Consensus Estimate of $5.79 per share, and up from $5.02 per share a year ago, representing an earnings surprise of 13.99% [1] - The company achieved revenues of $1.09 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.57%, and an increase from $1.01 billion year-over-year [2] - Over the last four quarters, Jazz has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Group 2 - The stock has gained approximately 11% since the beginning of the year, outperforming the S&P 500's gain of 1.7% [3] - The current consensus EPS estimate for the upcoming quarter is $4.34 on revenues of $981.29 million, and for the current fiscal year, it is $22.11 on revenues of $4.33 billion [7] - The Medical - Biomedical and Genetics industry, to which Jazz belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8]

Revenue Expectations and Growth - The company expects total revenue for 2024 to be in the range of $4.0 billion to $4.1 billion, with a significant portion driven by Xyrem and its acquired products[12]. - The company has achieved 20 consecutive years of year-over-year revenue growth, with a compound annual growth rate (CAGR) of 13.5% from 2018 to 2024[16]. - The company reported over $1.1 billion in revenue from Zepzelca since its launch in mid-2020, indicating strong market acceptance[14]. - The company anticipates that Epidiolex will reach blockbuster status in 2025, with peak sales potential exceeding $2 billion[14]. - The company expects to meet its 2024 guidance for total, neuroscience, and oncology revenues, reflecting confidence in its diversified portfolio[15]. Pipeline and Product Development - The company is positioned to submit a supplemental New Drug Application (sNDA) for 1L ES-SCLC in the first half of 2025, following positive Phase 3 trial results[28]. - The company has a robust pipeline with key programs in various phases, including Zanidatamab and Zepzelca, aimed at addressing significant unmet medical needs[21]. - The company has initiated a Phase 3 confirmatory trial for Zanidatamab in 1L GEA, with top-line results expected in 2025[24]. - Ziihera (zanidatamab-hrii) approved in the U.S. for previously treated, unresectable or metastatic HER2+ biliary tract cancer (BTC) with potential EMA approval as early as 2Q25[40]. - The Phase 3 EmpowHER trial initiated in 2H24 aims to explore zanidatamab's efficacy in various HER2+ cancers, expanding its therapeutic potential[40]. Financial Strength and Capital Allocation - The company has approximately $2.6 billion in cash and cash equivalents, providing financial strength for strategic transactions and partnerships[14]. - Jazz Pharmaceuticals maintains a disciplined capital allocation strategy with ~$1.0 billion in cash from operations and $2.6 billion in cash, cash equivalents, and investments as of September 30, 2024[54]. Product Performance and Market Needs - Xywav annualizing over $1.5 billion in net product sales as of 3Q24, remains the 1 branded treatment for narcolepsy[50]. - Rylaze generated approximately $1.1 billion in revenue since its launch in mid-2021, addressing a critical need for patients with hypersensitivity reactions to E. coli-derived asparaginase[46]. - Epidiolex poised to reach blockbuster status in 2025, with ongoing education on treatment synergies and growth opportunities in the adult patient setting[48]. - Significant unmet need in extensive-stage small cell lung cancer (SCLC), with ~30,000 1L SCLC patients in the U.S. and a plan to submit sNDA for 1L ES-SCLC in 1H25[44]. Strategic Focus and Growth Initiatives - The company has a diverse product mix, with significant revenue contributions from its oncology, neuroscience, and sleep medicine segments[31]. - Ziihera's launch supported by a proven oncology team and established infrastructure, focusing on key customer engagement and patient support services[38]. - The company is advancing its differentiated pipeline to support future growth, including ongoing trials for multiple HER2-expressing indications[40]. - Jazz Pharmaceuticals is focused on diversifying transactions to drive long-term growth and shareholder value[57].

Core Insights - Jazz Pharmaceuticals reported record total revenues of over $4 billion for the year 2024, reflecting a 6% year-over-year growth [2][6][14] - The company anticipates continued growth in 2025, with guidance for total revenues between $4.15 billion and $4.40 billion, representing a 5% growth at the midpoint [7][22] Financial Performance - Total revenues for Q4 2024 were $1.1 billion, up from $1.0 billion in Q4 2023 [10][12] - GAAP net income for 2024 was $560.1 million, or $8.65 per diluted share, compared to $414.8 million, or $6.10 per diluted share, for 2023 [10][11] - Non-GAAP adjusted net income for 2024 was $1.37 billion, or $20.90 per diluted share, compared to $1.30 billion, or $18.29 per diluted share, for 2023 [11][12] Revenue Breakdown - Xywav net product sales increased 16% to $1.47 billion in 2024, while Epidiolex/Epidyolex sales rose 15% to $972.4 million [6][12] - Oncology revenues surpassed $1.1 billion in 2024, growing 9% year-over-year [6][16] - Zepzelca net product sales increased 11% to $320.3 million in 2024 [13][16] Pipeline Developments - Ziihera was approved for 2L HER2+ biliary tract cancer and achieved first sales in December 2024 [6][13] - Upcoming top-line data from the HERIZON-GEA-01 trial in 1L gastroesophageal adenocarcinoma is expected in the second half of 2025 [2][7] - The company plans to submit a supplemental New Drug Application for Zepzelca in combination with Tecentriq for 1L extensive-stage small cell lung cancer in the first half of 2025 [7][13] Operating Expenses - Total operating expenses for 2024 were $3.35 billion, compared to $3.26 billion in 2023 [10][12] - Selling, general and administrative expenses increased due to higher compensation-related expenses and increased investment in sales and marketing [20][21] Cash Flow and Balance Sheet - The company generated over $1.4 billion in cash from operations in 2024 [7][19] - As of December 31, 2024, cash, cash equivalents, and investments totaled $3.0 billion, with long-term debt at $6.2 billion [19][37]

Core Viewpoint - Analysts expect Jazz Pharmaceuticals to report quarterly earnings of $5.79 per share, reflecting a year-over-year increase of 15.3%, with revenues projected at $1.06 billion, up 4.8% from the previous year [1] Revenue Estimates - Analysts estimate 'Revenues- Product sales, net' at $995.17 million, indicating a change of +2.9% year-over-year [4] - 'Total revenues- Neuroscience- Oxybate- Xywav' is projected to reach $393.28 million, suggesting a change of +16.7% year-over-year [4] - 'Total revenues- Neuroscience- Epidiolex/Epidyolex' is expected to be $264.59 million, reflecting a change of +10% from the prior year [5] - 'Total revenues- Neuroscience- Sativex' is estimated at $6.58 million, indicating a change of +28.2% year-over-year [5] - 'Total revenues- Neuroscience- Oxybate (Xywav & Xyrem)' is forecasted at $443.06 million, showing a change of -0.2% from the previous year [6] - 'Total revenues- Neuroscience- Total' is expected to reach $714.23 million, indicating a change of +3.6% year-over-year [6] - 'Total revenues- Oncology- Total' is projected at $276.22 million, reflecting a change of +0.9% from the prior year [6] - 'Total revenues- Oncology- Rylaze' is estimated at $99.81 million, indicating a change of -1.9% year-over-year [7] - 'Total revenues- Oncology- Defitelio/defibrotide' is expected to be $46.52 million, reflecting a change of -8.9% from the previous year [7] - 'Total revenues- Oncology- Vyxeos' is projected at $42.05 million, indicating a change of -10.4% year-over-year [8] - 'Total revenues- Oncology- Zepzelca' is expected to reach $91.31 million, reflecting a change of +23.4% from the prior year [8] - 'Total revenues- Other' is estimated at $3.84 million, indicating a change of -6.1% from the previous year [8] Stock Performance - Jazz shares have increased by +11.7% over the past month, outperforming the Zacks S&P 500 composite, which rose by +2.6% [9]

Group 1: Jazz Pharmaceuticals - Jazz Pharmaceuticals (JAZZ) shares increased by 5.2% to close at $129.98, driven by notable trading volume and optimism regarding its diverse portfolio of marketed drugs, including therapies for sleep disorders, epilepsy, and cancer treatments [1] - The company is expected to report quarterly earnings of $5.79 per share, reflecting a year-over-year increase of 15.3%, with revenues projected at $1.06 billion, up 4.8% from the previous year [2] - The consensus EPS estimate for Jazz has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] Group 2: Dianthus Therapeutics - Dianthus Therapeutics, Inc. has a consensus EPS estimate of -$0.85 for the upcoming report, representing a 19.7% decline from the previous year [4] - Dianthus currently holds a Zacks Rank of 4 (Sell), indicating weaker performance expectations compared to Jazz Pharmaceuticals [4]

Core Viewpoint - Jazz Pharmaceuticals plc will report its 2024 full year and fourth quarter financial results on February 25, 2025, after U.S. market close, followed by a live audio webcast to discuss the results and provide updates [1]. Group 1: Financial Results Announcement - The financial results for the full year and fourth quarter of 2024 will be announced on February 25, 2025 [1]. - A live audio webcast will take place at 4:30 p.m. ET / 9:30 p.m. GMT to discuss the financial results [1]. Group 2: Webcast Access Information - Interested parties can access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website [2]. - It is recommended that participants register at least 15 minutes prior to the scheduled webcast for a timely connection [2]. Group 3: Company Overview - Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases with limited therapeutic options [4]. - The company has a diverse portfolio, including therapies for sleep disorders, epilepsy, and a growing range of cancer treatments [4]. - Jazz is headquartered in Dublin, Ireland, with research and development facilities and employees in multiple countries [4].

Core Viewpoint - Jazz Pharmaceuticals (JAZZ) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Earnings Performance - The company has a solid track record of surpassing earnings estimates, with an average surprise of 17.04% over the last two quarters [2]. - In the last reported quarter, Jazz achieved earnings of $6.61 per share, exceeding the Zacks Consensus Estimate of $5.47 per share by 20.84%. In the previous quarter, it reported earnings of $5.30 per share against an expectation of $4.68 per share, resulting in a surprise of 13.25% [3]. Earnings Estimates and Predictions - Estimates for Jazz have been trending upward, influenced by its history of earnings surprises. The stock currently has a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of another earnings beat [4]. - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise, suggesting that out of 10 such stocks, approximately seven may exceed consensus estimates [5]. Earnings ESP and Analyst Sentiment - Jazz has an Earnings ESP of +1.27%, indicating that analysts are optimistic about its near-term earnings potential. This positive ESP, combined with a Zacks Rank of 3, suggests a possible upcoming earnings beat [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate than earlier predictions [6].

Group 1 - Jazz Pharmaceuticals plc (NASDAQ: JAZZ) shares have experienced a significant rally following a positive 3Q24 earnings report on November 6th and subsequent FDA approval two weeks later [4] - The company operates in the neuroscience and oncology sectors, indicating a focus on high-potential therapeutic areas [4] - The current CEO of Jazz Pharmaceuticals has been highlighted, suggesting leadership stability during this growth phase [4] Group 2 - The Biotech Forum has been actively discussing profitable buy-write or covered call strategies on selected biotech stocks, indicating a strong interest in options trading within the sector [2] - The forum provides a model portfolio featuring 12-20 high upside biotech stocks, showcasing a curated investment approach [3] - Weekly market commentary and portfolio updates are offered, reflecting a commitment to ongoing analysis and investor engagement [3]